Literature DB >> 20298358

Economics of COPD: literature review and experiences from field work.

R Nielsen1, M Klemmetsby, A Gulsvik.   

Abstract

INTRODUCTION: The burden of diseases should be described in terms of costs. The available literature gives imprecise estimates of costs of chronic obstructive pulmonary disease (COPD) in the Nordic populations. Previous studies have methodological weaknesses related to choice of disease criteria, the use of highly selected populations and insufficient specification of the cost process. There are no robust estimates concerning the economics of COPD in Norway.
METHODS: We have conducted a 1 year follow-up cost of illness study in a general population, recruiting ever-smoking Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2+ COPD patients and ever-smokers without COPD. We have used diaries to recollect data, and comprehensive questionnaires to cover all costs of COPD.
RESULTS: The main challenges were the participants' unwillingness to complete diaries, the large amount of information and the logistics related to following up 476 individuals on four occasions during one year.
CONCLUSIONS: We doubt the effect of diaries. However, we recommend a detailed planning of logistics and to emphasize main cost drivers.

Entities:  

Mesh:

Year:  2008        PMID: 20298358     DOI: 10.1111/j.1752-699X.2008.00092.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  2 in total

1.  Productivity losses in chronic obstructive pulmonary disease: a population-based survey.

Authors:  Marta Erdal; Ane Johannessen; Jan Erik Askildsen; Tomas Eagan; Amund Gulsvik; Rune Grønseth
Journal:  BMJ Open Respir Res       Date:  2014-12-01

2.  Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients.

Authors:  Marta Erdal; Ane Johannessen; Tomas Mikal Eagan; Per Bakke; Amund Gulsvik; Rune Grønseth
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.